Zampieri Nicola, Pellegrino Maristella, Ottolenghi Alberto, Camoglio Francesco Saverio
Pediatric Surgical Unit, Department of Anesthetic and Surgical Sciences, University of Verona, Policlinico G.B.Rossi, piazzale L.A.Scuro n.1, 37134, Verona, Italy.
Pediatr Surg Int. 2010 May;26(5):505-8. doi: 10.1007/s00383-010-2574-9. Epub 2010 Feb 17.
Subclinical varicocele is a relative rare condition. The aim of this study is to identify the role of bioflavonoids in the management of subclinical varicocele.
We analyzed the medical charts of patients treated for subclinical varicocele with bioflavonoids between 1999 and 2004; inclusion criteria were created before treatment. Short and long-term results after treatment were studied and compared with untreated patients.
One hundred and sixty-eight patients with left subclinical varicocele were included in the study. Long-term results showed a possible correlation between use of bioflavonoids and lesser rate of clinical progression to palpable varicocele (11 vs. 31%), higher rate of stable vein reflux (47 vs. 38%) and higher resolution rate (41 vs. 31%) (p > 0.05). Bioflavonoids did not show any protective factor against testicular growth arrest.
Subclinical varicocele should be considered as the starting point of varicocele, and although the use of bioflavonoids in patients with subclinical varicocele could reduce the development of palpable varicocele, it cannot prevent the onset of testicular growth arrest.
亚临床型精索静脉曲张是一种相对罕见的病症。本研究的目的是确定生物类黄酮在亚临床型精索静脉曲张治疗中的作用。
我们分析了1999年至2004年间接受生物类黄酮治疗的亚临床型精索静脉曲张患者的病历；在治疗前制定了纳入标准。研究了治疗后的短期和长期结果，并与未治疗的患者进行了比较。
168例左侧亚临床型精索静脉曲张患者纳入研究。长期结果显示，使用生物类黄酮与临床进展为可触及的精索静脉曲张的发生率较低（11%对31%）、静脉反流稳定率较高（47%对38%）以及消退率较高（41%对31%）之间可能存在相关性（p>0.05）。生物类黄酮未显示出任何预防睾丸生长停滞的保护因素。
亚临床型精索静脉曲张应被视为精索静脉曲张的起始阶段，虽然在亚临床型精索静脉曲张患者中使用生物类黄酮可减少可触及的精索静脉曲张的发生，但它不能预防睾丸生长停滞的发生。
